Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using theemail support widget if the problem persists.
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermedia...
Data could not be retrieved
INDSWFTLAB | Peers | Sector | |
---|---|---|---|
Market Cap | 4.911 B | 18.001 B | 5.212 B |
Price % of 52 Week High | Premium | 69.0% | 59.6% |
Dividend Yield | 0.0% | 0.1% | 0.0% |
Shareholder Yield | Premium | 0.6% | -0.7% |
1 Year Price Total Return | -35.2% | -4.0% | -14.8% |
Beta (5 Year) | 0.41 | 0.47 | 0.64 |
No data available
DuPont ROE AnalysisView Updated 5 hours ago |
Earnings Power ValueView Updated 17 hours ago |
EV / EBIT MultiplesView Updated 17 hours ago |
EV / EBITDA MultiplesView Updated 17 hours ago |
P/E MultiplesView Updated 17 hours ago |
Price / Book MultiplesView Updated 17 hours ago |
Price / Sales MultiplesView Updated 17 hours ago |
EV / Revenue MultiplesView Updated 17 hours ago |
CAPM WACC ModelView Updated 1 day ago |
10Y DCF EBITDA ExitView Updated 17 hours ago |
10Y DCF Revenue ExitView Updated 17 hours ago |
10Y DCF Growth ExitView Updated 17 hours ago |
5Y DCF EBITDA ExitView Updated 17 hours ago |
5Y DCF Revenue ExitView Updated 17 hours ago |
5Y DCF Growth ExitView Updated 17 hours ago |
10Y Historical FinancialsView Updated 5 hours ago |
5Y Historical FinancialsView Updated 5 hours ago |
(INR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
---|---|---|---|---|---|
Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
Income Statement | |||||
Revenue | 12,159 | 12,973 | 4,635 | 2,875 | 87 |
Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
EBITDA | 2,389 | 2,683 | 914 | 525 | (15) |
Balance Sheet | |||||
Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Debt | 8,621 | 166 | 164 | 8,016 | 164 |
Cash Flow Statement | |||||
Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Free Cash Flow | 1,818 | (2,076) | (3,200) | 0.00 | - |